The Therapeutic Effects of Baclofen as Adjunctive Therapy on Positive and Negative Symptoms of Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial
Middle East Journal of Rehabilitation and Health Studies · 24.05.2026 · 13 (3)
DOI: 10.5812/mejrh-169316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Middle East Journal of Rehabilitation and Health Studies, online erschienen am 24.05.2026. Verfasst von Samira Saheli und 4 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Schizophrenia is a chronic psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, and negative symptoms, including affective flattening and social withdrawal.
Objectives
This study investigated the adjunctive effects of baclofen across multiple symptom domains, including positive and negative symptoms, anxiety, depression, disorganization, and agitation, and assessed motor safety.
Methods
In this double-blind, randomized, placebo-controlled trial, 144 hospitalized patients receiving risperidone were assigned to receive baclofen (n = 72) or placebo (n = 72) for 8 weeks. Symptom severity was assessed at baseline and at weeks 2, 4, and 8 using the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Abnormal Involuntary Movement Scale (AIMS). Repeated-measures ANOVA was used to evaluate the effects of time, group, and the time × group interaction. Analyses were conducted using a per-protocol approach.
Results
Baseline demographic characteristics, including age and sex, were comparable between the groups. Compared with placebo, baclofen significantly reduced positive, negative, anxiety, depression, disorganization, and agitation symptoms (all P < 0.001). Improvement in positive symptoms emerged by week 2, whereas improvement in negative symptoms became more pronounced from week 4 onward. Effect sizes ranged from partial η2 = 0.100 to 0.365, indicating small-to-large interaction effects. Baclofen was well tolerated; 8 patients (11.1%) discontinued treatment because of mild adverse effects, including dizziness or nausea, and mild psychomotor slowing was observed in 8.3% of patients, with no rigidity, fasciculations, or clinically significant extrapyramidal symptoms.
Conclusions
Baclofen demonstrated statistically significant adjunctive effects across multiple symptom domains of schizophrenia over 8 weeks, with a favorable short-term motor safety profile. These preliminary findings from a single-center study with fixed dosing require confirmation in larger, multicenter trials.
Zitieren
APA
Saheli, S., Behrouzian, F., Pourshams, M., Bitaraf, S., & Riahi, F. (2026). The Therapeutic Effects of Baclofen as Adjunctive Therapy on Positive and Negative Symptoms of Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Middle East Journal of Rehabilitation and Health Studies, 13(3). https://doi.org/10.5812/mejrh-169316
Vancouver
Saheli S, Behrouzian F, Pourshams M, Bitaraf S, Riahi F. The Therapeutic Effects of Baclofen as Adjunctive Therapy on Positive and Negative Symptoms of Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Middle East Journal of Rehabilitation and Health Studies. 2026;13(3). doi:10.5812/mejrh-169316
BibTeX
@article{Saheli2026,
author = {Saheli, Samira and Behrouzian, Forouzan and Pourshams, Maryam and Bitaraf, Saeid and Riahi, Forough},
title = {The Therapeutic Effects of Baclofen as Adjunctive Therapy on Positive and Negative Symptoms of Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial},
journal = {Middle East Journal of Rehabilitation and Health Studies},
year = {2026},
volume = {13},
number = {3},
doi = {10.5812/mejrh-169316}
}
EUVIMED